Hemogenyx Awarded Grant
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has secured a $120,000 G-Rex® grant from ScaleReady, in partnership with Wilson Wolf Manufacturing and Cell Ready. The grant will support the optimization and scale-up of manufacturing for HG-CT-1, the company's lead CAR-T product candidate currently in Phase I trials for relapsed/refractory acute myeloid leukemia.
The funding will enable development of a closed-system, G-Rex®-based manufacturing platform, aimed at reducing production complexity, enhancing regulatory compliance, and lowering per-patient manufacturing costs. The grant includes technical consulting support in lean bioprocessing, regulatory strategy, and process engineering to support future clinical and commercial-scale manufacturing.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) ha ottenuto una contributo di 120.000 $ G-Rex® da ScaleReady, in collaborazione con Wilson Wolf Manufacturing e Cell Ready. Il finanziamento sosterrà l'ottimizzazione e la scalabilità della produzione di HG-CT-1, il principale candidato CAR-T dell'azienda attualmente in fase I di sperimentazione per la leucemia mieloide acuta recidivante/refrattaria.
Il finanziamento permetterà lo sviluppo di una piattaforma di produzione chiusa basata su G-Rex®, con l'obiettivo di ridurre la complessità produttiva, migliorare la conformità normativa e abbassare i costi di produzione per paziente. Il contributo include anche supporto tecnico in consulenza per bioprocessi snelli, strategia regolatoria e ingegneria di processo, a sostegno della produzione futura a livello clinico e commerciale.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) ha asegurado una subvención de 120,000 $ G-Rex® de ScaleReady, en asociación con Wilson Wolf Manufacturing y Cell Ready. La subvención apoyará la optimización y ampliación de la fabricación de HG-CT-1, el principal candidato a producto CAR-T de la compañía, actualmente en ensayos de fase I para leucemia mieloide aguda en recaída/refractaria.
La financiación permitirá el desarrollo de una plataforma de fabricación cerrada basada en G-Rex®, destinada a reducir la complejidad de producción, mejorar el cumplimiento regulatorio y disminuir los costos de fabricación por paciente. La subvención incluye soporte técnico en consultoría para bioprocesos lean, estrategia regulatoria e ingeniería de procesos para apoyar la fabricación a escala clínica y comercial futura.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF)는 Wilson Wolf Manufacturing 및 Cell Ready와 협력하여 ScaleReady로부터 120,000달러 규모의 G-Rex® 보조금을 확보했습니다. 이 보조금은 재발/불응성 급성 골수성 백혈병에 대해 현재 1상 임상 중인 회사의 주력 CAR-T 제품 후보인 HG-CT-1의 제조 최적화 및 규모 확장을 지원합니다.
이 자금은 생산 복잡성을 줄이고 규제 준수를 강화하며 환자당 제조 비용을 낮추기 위한 G-Rex® 기반 폐쇄형 제조 플랫폼 개발을 가능하게 합니다. 보조금에는 향후 임상 및 상업적 규모 제조를 지원하기 위한 린 바이오프로세싱, 규제 전략 및 공정 엔지니어링에 대한 기술 컨설팅 지원도 포함되어 있습니다.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) a obtenu une subvention G-Rex® de 120 000 $ de ScaleReady, en partenariat avec Wilson Wolf Manufacturing et Cell Ready. Cette subvention soutiendra l'optimisation et la montée en échelle de la fabrication de HG-CT-1, le principal candidat produit CAR-T de la société actuellement en essais de phase I pour une leucémie myéloïde aiguë en rechute/réfractaire.
Le financement permettra de développer une plateforme de fabrication fermée basée sur G-Rex®, visant à réduire la complexité de production, améliorer la conformité réglementaire et diminuer les coûts de fabrication par patient. La subvention inclut un support technique en conseil pour la bioproduction lean, la stratégie réglementaire et l'ingénierie des procédés afin de soutenir la fabrication à l'échelle clinique et commerciale future.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) hat einen G-Rex®-Zuschuss in Höhe von 120.000 $ von ScaleReady in Partnerschaft mit Wilson Wolf Manufacturing und Cell Ready erhalten. Der Zuschuss unterstützt die Optimierung und Skalierung der Herstellung von HG-CT-1, dem führenden CAR-T-Produktkandidaten des Unternehmens, der sich derzeit in Phase-I-Studien für rezidivierende/refraktäre akute myeloische Leukämie befindet.
Die Finanzierung ermöglicht die Entwicklung einer geschlossenen, G-Rex®-basierten Herstellungsplattform, die darauf abzielt, die Produktionskomplexität zu reduzieren, die regulatorische Compliance zu verbessern und die Herstellungskosten pro Patient zu senken. Der Zuschuss umfasst technische Beratungsleistungen zu schlanken Bioprozessen, regulatorischer Strategie und Prozessengineering zur Unterstützung der zukünftigen klinischen und kommerziellen Herstellung.
- Secured $120,000 grant to optimize CAR-T manufacturing process
- Access to technical consulting support for regulatory and process optimization
- Potential reduction in per-patient manufacturing costs through G-Rex platform
- Validation from industry leaders ScaleReady, Wilson Wolf, and Cell Ready
- Current manufacturing process requires optimization for commercial viability
- Complex regulatory compliance requirements for CAR-T production
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
LONDON, UK / ACCESS Newswire / July 16, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been awarded a
The Grant will enable the Company to further develop a closed-system, G-Rex®-based, manufacturing platform, which is expected to reduce production complexity, streamline regulatory compliance, and significantly lower per-patient manufacturing costs. These advances are critical to the long-term commercial viability of autologous CAR-T therapies such as HG-CT-1.
The Grant also includes Company access to technical consulting in lean bioprocessing, regulatory and CMC strategy, and process engineering, strengthening Hemogenyx's capacity to support future clinical and commercial-scale manufacturing.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"This Grant provides targeted support for one of the most important aspects of CAR-T development: cost-effective, scalable manufacturing. As we continue to advance HG-CT-1 through clinical trials, optimizing our cGMP production process will be essential to maximizing both patient access and shareholder value. We are pleased to be working with industry leaders ScaleReady, Wilson Wolf, and Cell Ready, and we view this collaboration as a strong validation of the promise of our platform."
The Company anticipates that the G-Rex optimization will also generate a robust data package supporting the adoption of next-generation G-Rex® "M" series bioreactor systems, which reduce operator intervention and enable greater automation.
Hemogenyx remains focused on executing its clinical and operational milestones and will continue to update the market on its progress.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the value of the G-Rex grant awarded to Hemogenyx (HOPHF)?
What is the purpose of Hemogenyx's HG-CT-1 CAR-T therapy?
How will the G-Rex grant benefit Hemogenyx's manufacturing process?
What stage of development is Hemogenyx's HG-CT-1 therapy in?
What technical support does the G-Rex grant include for Hemogenyx?
